ES2124258T3 - Produccion del virus de la hepatitis a. - Google Patents

Produccion del virus de la hepatitis a.

Info

Publication number
ES2124258T3
ES2124258T3 ES92910403T ES92910403T ES2124258T3 ES 2124258 T3 ES2124258 T3 ES 2124258T3 ES 92910403 T ES92910403 T ES 92910403T ES 92910403 T ES92910403 T ES 92910403T ES 2124258 T3 ES2124258 T3 ES 2124258T3
Authority
ES
Spain
Prior art keywords
production
hepatitis virus
hepatitis
virus
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92910403T
Other languages
English (en)
Inventor
David Victor Sangar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma Ltd
Original Assignee
Evans Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans Medical Ltd filed Critical Evans Medical Ltd
Application granted granted Critical
Publication of ES2124258T3 publication Critical patent/ES2124258T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN PROCESO PARA LA PROPAGACION DE VIRUS DE HEPATITIS A, CUYO PROCESO COMPRENDE CULTIVAR CELULAS INFECTADAS CON EL VIRUS EN UN MEDIO DE CULTIVO ACUOSO, EN EL CUAL LA CONCENTRACION DE CLORURO SODICO ES DESDE 30 MM A 170 MM SOBRE LA CONCENTRACION ISOTONICA DE CLORURO SODICO; Y PRODUCCION DE UNA VACUNA A PARTIR DE EL.
ES92910403T 1991-05-24 1992-05-22 Produccion del virus de la hepatitis a. Expired - Lifetime ES2124258T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111230A GB9111230D0 (en) 1991-05-24 1991-05-24 Virus production

Publications (1)

Publication Number Publication Date
ES2124258T3 true ES2124258T3 (es) 1999-02-01

Family

ID=10695533

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92910403T Expired - Lifetime ES2124258T3 (es) 1991-05-24 1992-05-22 Produccion del virus de la hepatitis a.

Country Status (6)

Country Link
EP (1) EP0586438B1 (es)
JP (1) JPH06508512A (es)
DE (1) DE69227368T2 (es)
ES (1) ES2124258T3 (es)
GB (1) GB9111230D0 (es)
WO (1) WO1992020786A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013158706A1 (en) * 2012-04-18 2013-10-24 The Trustees Of Princeton University Method to produce virus in cultured cells supplemented with alpha-ketoglutarate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT71739B (en) * 1979-09-04 1982-01-26 Merck & Co Inc Process for preparing a cell culture of hepatitis a virus
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)

Also Published As

Publication number Publication date
DE69227368T2 (de) 1999-03-18
WO1992020786A1 (en) 1992-11-26
EP0586438A1 (en) 1994-03-16
EP0586438B1 (en) 1998-10-21
JPH06508512A (ja) 1994-09-29
DE69227368D1 (de) 1998-11-26
GB9111230D0 (en) 1991-07-17

Similar Documents

Publication Publication Date Title
ES2137178T3 (es) Producto sanguineo en el cual los virus han sido inactivados por medio de calor y/o detergente.
NO20026044L (no) Behandling av humant papillomavirus
ATE376059T1 (de) Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
BR9712138A (pt) Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
DE3789399D1 (de) Herstellung von Vakkzinen gegen Hepatitis B-Virus.
AR022510A1 (es) Formulaciones de vacunas contra el papilomavirus humano
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
ES2042751T3 (es) Nuevo procedimiento para la purificacion de viriones de la hepatitis a.
ATE116637T1 (de) Sulfonische stilbenderivate zur behandlung von viruserkrankungen.
EA200500834A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
ES8900007A1 (es) Un metodo para producir normas orales frente a virus de hepatitis-b.
ES2099277T3 (es) Procedimiento de fabricacion de una solucion acuosa industrial de cloruro de sodio.
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
PT777669E (pt) Utilizacao de succinato de 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral
ES2058100T3 (es) Vacuna combinada.
AR009604A1 (es) Procedimiento para la separacion de clna de una solucion de cili
ES2124258T3 (es) Produccion del virus de la hepatitis a.
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
PE61699A1 (es) Composicion farmaceutica de lamivudina
DE69718911D1 (de) Interleukin - 8 als antivirale- und antitumorwirkstoffe
TR200606983T1 (tr) Nodavirüs-VLP bağışıklaştırma bileşimi
ES2137544T3 (es) Procedimiento para la preparacion de un preparado biologico terapeutico sin riesgo de infeccion por virus.
ES2062502T3 (es) Una proteina de factor i pura y un procedimiento para obtener dicha proteina.
Calder Effect of Nicotinic Acid on Myocardial Systole, Coronary Flow, and Arrhythmias of Isolated Heart

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 586438

Country of ref document: ES